Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Antengene Corporation Limited ( (HK:6996) ) is now available.
Antengene has appointed Dr. Bing Hou as Chief Scientific Officer, reinforcing its commitment to an innovation-led R&D model and a stronger internal research engine. Reporting directly to founder, chairman and CEO Dr. Jay Mei, Dr. Hou will oversee drug discovery, translational medicine and CMC, with a mandate to advance a next-generation pipeline leveraging the company’s proprietary platforms.
Under Dr. Hou’s scientific leadership since 2019, Antengene has built its AnTenGager T-cell engager 2.0 platform and progressed programs such as ATG-201 for B cell-related autoimmune diseases, while expanding a suite of first- and best-in-class candidates. His promotion is expected to accelerate development of key assets including TCEs, the B7-H3 x PD-L1 ADC ATG-125, and the αCD3-TGF-β fusion protein ATG-207, supporting Antengene’s bid to strengthen its global pipeline and competitive position in oncology and autoimmune therapies.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$5.74 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a global biotechnology company focused on innovation-driven research and development in oncology and autoimmune diseases. The company develops next-generation therapeutics, including T-cell engagers, bispecific antibody-drug conjugates, and other platform-based medicines targeting significant unmet medical needs worldwide.
Average Trading Volume: 3,468,064
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.08B
See more data about 6996 stock on TipRanks’ Stock Analysis page.